MétaCan
Menu
Back to cohort
Record W4248940072 · doi:10.1093/jnci/dji217

RESPONSE: Re: Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial

2005· article· en· W4248940072 on OpenAlexaffabout
Joseph Ragaz, Ivo A. Olivotto, Kenneth S. Wilson, John J. Spinelli, Ralph E. Durand

Bibliographic record

VenueJNCI Journal of the National Cancer Institute · 2005
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBreast Cancer Treatment Studies
Canadian institutionsMcGill UniversityBC Cancer Agency
Fundersnot available
KeywordsMedicineRandomized controlled trialRadiation therapyBreast cancerChemotherapyOncologyAdjuvantInternal medicineAdjuvant chemotherapyCancerAdjuvant radiotherapySurgery

Abstract

fetched live from OpenAlex

At 20 years of follow-up, we observed a sustained overall mortality reduction of 27% ( P = .03) in patients receiving locoregional radiotherapy. The tests of interaction performed for all categories of survival showed no difference between subgroups of patients with four or more involved axillary nodes compared with one to three involved axillary nodes ( 1 ) . The relevance of our findings in relation to current treatments has been addressed at length in our Discussion and in the accompanying editorial ( 2 ) . Several points merit emphasis. First, we acknowledge that radiation therapy techniques have changed over time. Improved use of computerized tomography (CT) planning with avoidance of high-dose radiation therapy to the heart may, in fact, yield a greater, rather than smaller, survival benefit from radiation therapy. Second, newer chemotherapy regimens are only marginally more effective than CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) and still require optimal locoregional therapy. Although the use of anthracyclines, taxanes, and transtuzumab may lead to more cardiac events, their consequences may be balanced by improved radiation therapy planning and heart shielding. Furthermore, among patients with one to three involved nodes, it is also possible to identify those with a higher risk as compared with lower risk of recurrence ( 3 , 4 ) with patients at higher risk having a more favorable balance between the benefits and risks of adjuvant radiation therapy ( 3 ) . Some of these selection criteria may have to be applied to current practice, because the mature results of new trials such as the Selective Use of Postoperative Radiotherapy after Mastectomy (SUPREMO) or the Canadian MA-20 will take more than a decade to appear and may still lack the statistical power to address all patient subsets. We agree that further studies of postoperative radiotherapy using current chemotherapy regimens and radiation techniques are warranted. We look forward in due course to reviewing the results of ongoing trials and the refined selection of patients for both adjuvant chemotherapy and radiotherapy. In summary, we believe our findings and those of the Danish Breast Cancer Cooperative Group ( 5 , 6 ) merit discussion with patients who have involved axillary lymph nodes after mastectomy ( 7 ) because appropriate application of these data could prevent thousands of breast cancer deaths annually worldwide.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: none
Teacher disagreement score0.949
Threshold uncertainty score0.102

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.004
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.251
Teacher spread0.243 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2005
Admission routes2
Has abstractno

Explore more

Same venueJNCI Journal of the National Cancer InstituteSame topicBreast Cancer Treatment StudiesFrench-language works237,207